Key terms
About BHVN
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BHVN news
Yesterday
12:27am ET
Maintaining Buy Rating: Biohaven’s BHV-1300 Shows Promising Efficacy and Safety Profile
Apr 17
4:10pm ET
Biohaven $200M Spot Secondary; price range $40.50-$42.00
Apr 17
4:09pm ET
Biohaven announces $200M common share offering
Apr 17
11:00am ET
Biotech Alert: Searches spiking for these stocks today
Apr 15
12:00pm ET
Biohaven falls -15.9%
Apr 15
10:17am ET
Biohaven presents update on Phase 1 single ascending dose study for BHV-1300
Apr 15
10:00am ET
Biohaven falls -4.3%
Apr 15
9:47am ET
Biohaven falls -5.8%
Apr 15
7:12am ET
Biohaven’s MoDE Pioneer Updates on BHV-1300 Progress
Apr 14
9:40pm ET
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Zoetis (ZTS) and Ginkgo Bioworks Holdings (DNA)
Apr 14
9:36pm ET
Buy Rating Affirmed for Biohaven Ltd. Amid Positive Clinical Outlook and Pipeline Potential
Apr 09
7:13am ET
Analysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA)
Apr 03
7:03pm ET
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
Mar 21
2:51am ET
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), AstraZeneca (AZN) and Biohaven Ltd. (BHVN)
Mar 07
10:29am ET
Biotech Alert: Searches spiking for these stocks today
Mar 06
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Mar 05
1:25am ET
Buy Rating Affirmed: Biohaven’s Innovative Pipeline and Financial Health Signal Promising Future
Mar 04
6:13am ET
Biohaven price target raised to $63 from $50 at H.C. Wainwright
Mar 03
9:25pm ET
Buy Rating Affirmed for Biohaven Ltd. on Strong Pipeline and Upcoming Drug Advancements
Mar 01
7:47am ET
Piper Sandler Remains a Buy on Biohaven Ltd. (BHVN)
Mar 01
7:31am ET
Analysts Are Bullish on Top Healthcare Stocks: Veeva Systems (VEEV), Xenon (XENE)
Mar 01
7:09am ET
Biohaven price target raised to $55 from $35 at TD Cowen
Feb 29
9:40pm ET
Analysts Offer Insights on Healthcare Companies: Seer (SEER) and Biohaven Ltd. (BHVN)
Feb 29
4:14pm ET
Biohaven reports Q4 non-GAAP EPS ($1.61), consensus ($1.41)
Feb 23
11:55am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Feb 23
11:00am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Feb 23
7:15am ET
Biohaven price target raised to $56 from $32 at JPMorgan
Feb 16
9:37am ET
UPS upgraded, Nike downgraded: Wall Street’s top analyst calls
Feb 16
7:12am ET
RBC Capital starts Biohaven at Outperform, sees BHV-7000 with over $1B potential
Feb 16
5:08am ET
Biohaven initiated with an Outperform at RBC Capital
Feb 12
8:32am ET
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Waters (WAT) and Biohaven Ltd. (BHVN)
No recent press releases are available for BHVN
BHVN Financials
Key terms
Ad Feedback
BHVN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BHVN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
